UBS downgrades Charter Hall Retail REIT (MQV) to a Hold
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Shield covers the Real Estate sector, focusing on stocks such as National Storage REIT, Charter Hall Retail REIT, and Arena REIT. According to TipRanks, Shield has an average return of 4.8% and an 85.71% success rate on recommended stocks.
In addition to UBS, Charter Hall Retail REIT also received a Hold from Jarden's Lou Pirenc in a report issued on June 6. However, on June 17, Ord Minnett maintained a Buy rating on Charter Hall Retail REIT (Frankfurt: MQV).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
UBS sees 'a further slowing in U.S. economic growth' in second half of 2025
-- UBS expects U.S. economic growth to decelerate to around 1% in 2025, citing a mix of fiscal fade, persistent inflation, and elevated interest rates. In a note to clients on Tuesday, the bank stated, 'We see a further slowing in US economic growth to ~1% in 2025,' and warned of a rising unemployment rate, projecting it will reach 4.6% by year-end. UBS analysts pointed to 'softening in private payrolls,' a decline in job listings in services, and higher effective tariffs as primary headwinds. The firm also noted that the average tariff rate is now roughly 16%, up from about 2% in 2024, and expects this to result in 'core PCE of ~3.4% by end-2025.' UBS sees these pressures weighing on real disposable income growth, which is already trailing personal consumption expenditures. While fiscal measures tied to the Big Beautiful Bill may support consumption, UBS noted these won't take effect until the first half of 2026. 'We see tariff impacts in 2H 2025,' the firm wrote. UBS also highlighted signs of stress in consumer and corporate credit. 'Our credit-based recession indicator is rising with a probability of a downturn through Q126 at 47%,' analysts said. Meanwhile, consumer delinquency rates are said to be climbing, especially in student and mortgage loans. Despite these pressures, the firm sees potential offsets, including credit usage and continued upper-income spending. UBS maintains a defensive positioning in credit, favoring higher quality and consumer non-cyclicals given tighter spreads compared to 2022. Related articles UBS sees 'a further slowing in U.S. economic growth' in second half of 2025 Victoria's Secret Exposed: The Warning Sign Behind the Stock's 52% Collapse Buy this massive AI stock into upcoming Q2 print: Morgan Stanley
Business Wire
an hour ago
- Business Wire
First Patient Enrolled in National Cancer Institute's Vanguard Study Evaluating Guardant Health's Shield Multi-Cancer Detection Test
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)'s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant's Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant's Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The Vanguard study was initiated following review and approval by the U.S. Food and Drug Administration (FDA) as part of the NCI's submission for an investigational device exemption (IDE). 'New screening technology like the Shield MCD test has the potential to detect multiple cancers earlier through a simple blood draw,' said Craig Eagle, MD, Guardant Health Global Chief Medical Officer. 'The earlier we can screen and diagnose cancers, the more options we can bring to patients and ultimately the more lives we can save. The Vanguard Study is a critical step in research to evaluate the role of this breakthrough technology in helping reduce cancer deaths.' The Vanguard Study, conducted by the Cancer Screening Research, a new NCI-sponsored clinical trials network, is enrolling individuals ages 45-75 who do not currently have cancer and who have not received a cancer diagnosis in the past five years. All participants will be offered standard cancer screenings as part of their care. Results from the study will inform the design of a much larger randomized controlled trial to evaluate the use of MCD tests for cancer screening. 'Initiation of the Vanguard Study is an exciting milestone, as we look to evaluate a new way to screen for cancer,' said Scott Ramsey, M.D., Ph.D., director of the Hutchinson Institute for Cancer Outcomes Research at Fred Hutch Cancer Center and principal investigator for the Vanguard Study. 'The study will help us learn more about multi-cancer detection tests and assess whether they can help people from all backgrounds find cancer early, when it may be easier to treat.' The Shield MCD test recently received Breakthrough Device Designation from the FDA for the multi-cancer screening of multiple cancer types including bladder, colorectal, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older who are at typical average risk for cancer. The FDA grants Breakthrough Device designation to a limited set of qualifying devices that have the potential to provide more effective treatment or diagnosis of life-threatening diseases, such as cancer, than current options. The goal of the FDA's Breakthrough Devices Program is to provide patients and healthcare providers with timely access to medical devices by speeding up their development, assessment and review. For more information, please visit the Fred Hutch Cancer Center Vanguard Study website. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
Yahoo
5 hours ago
- Yahoo
Evercore, UBS lead M&A financial advisory in Asia-Pacific for H1 2025
Evercore and UBS have emerged as the leading financial advisers for mergers and acquisitions (M&A) during the first half (H1) of 2025 in the Asia-Pacific (APAC) region, according to the latest league table from GlobalData, a data and analytics firm. GlobalData's deals database indicates that Evercore secured the top position in terms of deal value, having advised on transactions totalling $11.1bn. UBS led in deal volume, providing advisory services for 19 deals. GlobalData lead analyst Aurojyoti Bose said: 'Evercore was the only adviser to surpass $10 billion mark in total deal value during H1 2025. Involvement in three billion-dollar deals* helped it occupy the top position by value. Apart from leading by value, Evercore also held the 10th position by volume during the review period. 'Meanwhile, UBS, which was the top adviser by volume in H1 2024, also managed to retain its leadership position by this metric in H1 2025. Apart from leading by volume, UBS also occupied the fifth position by value.' Following Evercore in the value-based rankings, Mitsubishi UFJ Financial took second place, advising on deals worth $8.7bn. Citi followed with $7.7bn, RBC Capital Markets with $5.7bn, and UBS with $4.3bn. In terms of deal volume, PwC ranked second with 12 deals, trailed by Ernst & Young with 11 deals. Although both Deloitte and Daiwa Securities Group had nine deals each, Deloitte took the fourth spot because of the deal value. GlobalData's league tables are based on the real-time tracking of thousands of company websites, advisory firm websites and other reliable sources available on the secondary domain. A dedicated team of analysts monitors all these sources to gather in-depth details for each deal, including adviser names. To ensure further robustness to the data, the company also seeks submissions of deals from leading advisers. "Evercore, UBS lead M&A financial advisory in Asia-Pacific for H1 2025" was originally created and published by Retail Banker International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
